Prev. Article Next Article Table of Contents

Article

Antibody-Catalyzed Oxidation of Δ⁹-Tetrahydrocannabinol

Supporting Info

Andrew P. Brogan,^† Lisa M. Eubanks,^† George F. Koob,^‡ Tobin J. Dickerson,*^† and Kim D. Janda*^†;

Contribution from the Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute for Research and Medicine, and the Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037

J. Am. Chem. Soc., 2007, 129 (12), pp 3698–3702

DOI: 10.1021/ja070022m

Publication Date (Web): March 3, 2007

†

Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, and the Worm Institute for Research and Medicine.

‡

Committee on the Neurobiology of Addictive Disorders.

In papers with more than one author, the asterisk indicates the name of the author to whom inquiries about the paper should be addressed.

, kdjanda@scripps.edu, ; , tobin@scripps.edu

Abstract

Marijuana abuse continues to plague society and the lack of effective treatments warrants concern. Catalytic antibodies capable of oxidatively degrading the major psychoactive component of marijuana, Δ⁹-tetrahydrocannabinol (Δ⁹-THC), are presented. The antibodies generate reactive oxygen species from singlet oxygen (¹O₂*), using riboflavin (vitamin B₂) and visible light as the ¹O₂* source. Cannabitriol was identified as the major degradation product of this reaction, demonstrating the ability of an antibody to catalyze a complex chemical transformation with therapeutic implications for treating marijuana abuse.

View: Full Text HTML | Hi-Res PDF